Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9751996 | 0.84 | NISCH (0.53) | ATMPOLBCASP6NISCHSIRT1 | |
| SCHEMBL3399484 | 0.81 | POLB (0.45) | ATMPOLBCASP6NISCHLMNA | |
| SCHEMBL9281031 | 0.81 | ATM (0.50) | ATMPOLBNISCHALOX5SIRT1 | |
| SCHEMBL29606554 | 0.78 | POLB (0.69) | ATMPOLBCASP6NISCHLMNA | |
| SCHEMBL2547829 | 0.78 | POLB (0.69) | ATMPOLBCASP6NISCHLMNA | |
| SCHEMBL1168607 | 0.77 | POLB (0.39) | POLBCASP6CA2 | |
| SCHEMBL12863013 | 0.77 | PTGS2 (0.42) | POLBCASP6CA2 | |
| SCHEMBL5477951 | 0.77 | NISCH (0.73) | ATMPOLBCASP6NISCHSIRT1 | |
| SCHEMBL440743 | 0.76 | ALDH1A1 (0.42) | POLBCASP6ALOX5MTNR1AGLS | |
| Formaldehyde SCHEMBL27560205 | 0.74 | POLB (0.64) | ATMPOLBCASP6NISCHLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118580226-A | Benzodioxolane amide-containing antitumor active compound and preparation method and application thereof | 江苏海洋大学 | 2024-09-03 | — | — | CN | claimed |
| EP-4709736-A2 | COMBINATIONS OF NANOPARTICLE-LOADED IMMUNE AGONISTS AND RAS TARGETED THERAPIES FOR TREATMENT OF CANCER | University Of Massachusetts (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024238486-A2 | COMBINATIONS OF NANOPARTICLE-LOADED IMMUNE AGONISTS AND RAS TARGETED THERAPIES FOR TREATMENT OF CANCER | UNIVERSITY OF MASSACHUSETTS (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-118580226-A | Benzodioxolane amide-containing antitumor active compound and preparation method and application thereof | 江苏海洋大学 | 2024-09-03 | — | — | CN | disclosed |
| CN-118580226-A | Benzodioxolane amide-containing antitumor active compound and preparation method and application thereof | 江苏海洋大学 | 2024-09-03 | — | — | CN | disclosed |
| CN-118580226-A | Benzodioxolane amide-containing antitumor active compound and preparation method and application thereof | 江苏海洋大学 | 2024-09-03 | — | — | CN | disclosed |
| EP-1768970-B1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-1968572-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-06 | — | — | EP | disclosed |
| WO-2007075752-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075751-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075834-A2 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075833-A2 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| EP-1768970-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-04 | — | — | EP | disclosed |
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006007436-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006007435-A1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | WO | disclosed |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-22 | — | — | US | disclosed |
| JP-2002068908-A | 1,3-BENZODIOXOLE-2-CARBONAMIDE DERIVATIVE, AGROCHEMICAL AND METHOD FOR PRODUCING THE SAME | DAINIPPON INK & CHEM INC | 2002-03-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041008-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | ATM 4460/4885POLB 4415/4885CASP6 3610/4885 |
| US-20050282887-A1 | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | SULT2A1, STS, GRIK5 | ATM 4460/4885POLB 4415/4885CASP6 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.